Form 4: MoonLake Immunotherapeutics Officer Acquires Stock Options

Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics, was granted stock options to purchase 139,273 Class A ordinary shares.

Summary

• On February 27, 2025, Kristian Reich, the Chief Scientific Officer of MoonLake Immunotherapeutics, was granted stock options to purchase 139,273 Class A ordinary shares.
• The exercise price of these options is $41.77 per share.
• The options vest in four equal annual installments starting on February 27, 2026, and continuing through February 27, 2029, contingent upon Reich's continued service to the company.
• The options expire on February 27, 2035.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, suggesting confidence in the company's future. The sentiment is neutral to positive.

Positives

• The granting of stock options to a key executive like the Chief Scientific Officer can be seen as a way to incentivize their continued service and align their interests with the company's long-term success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the company's performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• The size of the grant is likely determined by a number of factors including the executive's role, experience, and the company's overall compensation strategy.
• Comparable companies such as argenx SE and UCB S.A. also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the Chief Scientific Officer to contribute to the company's success, which could benefit all stakeholders.

Key Dates